Minerva Neurosciences Reveals Data From Its Open-Label Safety Trial Evaluating Roluperidone Co-Administered With Olanzapine At SIRS 2026; Trial Demonstrated No Safety Concerns When Co-Administering Roluperidone And Olanzapine

Minerva Neurosciences, Inc. (NASDAQ: NERV) presented data from its open-label safety trial evaluating the co-administration of roluperidone and olanzapine at the 2026 Schizophrenia International Research Society Annual Congress. The trial demonstrated no safety concerns, with no clinically significant adverse effects or meaningful pharmacokinetic and pharmacodynamic changes observed during the combined administration. The findings were presented by Chief Medical Officer Michael Davidson, MD.